← Leaderboards
Sandhya Vasan
Henry M. Jackson Fdn For The Adv Mil/Med
$13,271,172
Attributed
$31,910,935
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.4M · FY2018–25$10M$7.5M$5M$2.5M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,910,935 · 4
By mechanism
UM1$27,959,644 · 2
R01$3,951,291 · 2
Top collaborators
- Dan H. Barouch6 shared
- John W Mellors6 shared
Most similar at Henry M. Jackson Fdn For The Adv Mil/Med
Same institution · by research overlap
- Afamefuna Okoye$9,317,654
- Gabriela S Dveksler$5,192,209
- Gary R. Matyas$15,326,105
- Ann E. Jerse$14,836,536
- Mark G. Lewis$2,495,135
Others in their field
Other Emerging Leaders on “Simian Human Immunodeficiency Virus”
- Julie Ake · National Institute Of Allergy And Infectious Diseases$22,000,000
- Wilton B Williams · Duke University$19,560,067
- Amitinder Kaur · Tulane University Of Louisiana$18,184,781
- Soumya Rahima Benhabbour · Univ Of North Carolina Chapel Hill$10,205,203
- Bette Korber · National Institute Of Allergy And Infectious Diseases$9,877,997
- Deanna A Kulpa · Emory University$8,444,989
Research focus
Simian Human Immunodeficiency VirusImmunologicsNeutralizing AntibodyHiv-1Macaca MulattaRegimenProgramsImmuneImmune ResponseSamplingPreventNovel StrategiesEngineeringVirusB-LymphocytesBaseAcademiaResidual StatePassive ImmunizationClinical DevelopmentIndustryBindingActive ImmunizationGovernment
Grant awards (10)
I4C 2.0: Immunotherapy for Cure$4,653,643
UM1 · FY2025 · AI
Designing HIV-1 envelope immunogens to maximize neutralization breadth through use of multiple founder envelope antigens$1,759,382
R01 · FY2025 · AI · contact PI
I4C 2.0: Immunotherapy for Cure$4,423,055
UM1 · FY2024 · AI
Designing HIV-1 envelope immunogens to maximize neutralization breadth through use of multiple founder envelope antigens$880,838
R01 · FY2024 · AI · contact PI
I4C 2.0: Immunotherapy for Cure$4,669,992
UM1 · FY2023 · AI
Designing HIV-1 envelope immunogens to maximize neutralization breadth through use of multiple founder envelope antigens$619,289
R01 · FY2023 · AI · contact PI
I4C 2.0: Immunotherapy for Cure$4,677,761
UM1 · FY2022 · AI
I4C 2.0: Immunotherapy for Cure$4,904,730
UM1 · FY2021 · AI
Combined Immunologic Approaches to Cure HIV-1$4,630,463
UM1 · FY2020 · AI
Preservation of adaptive immunity leads to HIV control upon treatment cessation.$691,782
R01 · FY2018 · AI · contact PI